Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $19.7B | $22.3B | $22.5B | $25.9B | $29.5B | $30.8B | $35.2B | $38.9B | $39.9B | $21.8B | $20.2B | $20.4B | $20.9B | $27.4B | $30.6B | $31.9B | $34.6B | $43.1B | $43.7B | $40.1B |
Discover the top 20 best undervalued stocks to buy for Dec 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Dec 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Dec 2024.
As of today, Abbott Laboratories's last 12-month Revenue is $41.2B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Abbott Laboratories's Revenue growth was 3.1%. The average annual Revenue growth rates for Abbott Laboratories have been 3.3% over the past three years, 5.6% over the past five years.
Over the last year, Abbott Laboratories's Revenue growth was 3.1%, which is higher than industry growth of 0.1%. It indicates that Abbott Laboratories's Revenue growth is Good.